Northrop Grumman CEO Kathy Warden announced $2.1 billion in capital expenditures for 2027 to expand manufacturing capacity and accelerate B-21 Raider production rates. The company expects higher output later this decade as it simultaneously pursues sustainment and modernization on the aircraft.
What's happening
- Northrop will spend approximately $2.1 billion in companywide capex during 2027, representing about 4.5 percent of sales, with much of that supporting B-21 capacity expansion.
- Capacity work will continue through 2028, with production rate increases expected to follow later in the decade.
- The company expects testing and production of the B-21 to increase in 2027 while longer-term manufacturing expansion is underway.
- Sustainment and modernization programs are running alongside manufacturing to support the aircraft's operational readiness.
Why it matters
- Increased B-21 production capacity directly addresses Air Force requirements for bomber fleet modernization, reducing supply risk for a critical strategic asset.
- The ramp addresses industrial base capacity constraints by bringing online dedicated manufacturing space, enabling higher throughput to meet future procurement schedules.
- Simultaneous sustainment work beginning during production indicates mature supply chain planning and reduces the risk of support bottlenecks later.
- Higher B-21 volumes will increase Northrop's Aeronautics Systems revenue, though rising bomber sales concentration may compress division operating margin.
Going deeper
- CEO Warden emphasized that successful ground and flight testing is reducing late-stage discovery risk, indicating manufacturing experience is improving production performance on fixed-price contracts.
- The company expects stronger operating performance, working capital management and tax optimization to offset the B-21 acceleration spending.
- Northrop maintained its 2027 adjusted free cash flow guidance at $3.3 billion to $3.7 billion despite the $2.1 billion capex increase.
Financial impact
- Capex of $2.1 billion will flow to the cash flow statement in 2027 as capital spending, reducing operating cash generation in that period.
- Higher B-21 testing and production in 2027 will contribute to revenue recognition in the Aeronautics Systems segment, though backlog translation depends on obligated funding from the Air Force.
- Increased B-21 share of Aeronautics Systems sales in 2027 will create margin pressure on the division as the high-volume production ramp offsets pricing on fixed-price contracts.
- The company's maintained free cash flow guidance of $3.3 billion to $3.7 billion for 2027 implies offsetting improvements in operations and working capital will substantially fund the capacity expansion.
The fine print
- Northrop acknowledges risk remains while completing outstanding low-rate initial production aircraft on fixed-price contracts.
- Capacity work extends through 2028, creating a two-year lag before production rate increases materialize, dependent on continued Air Force funding.
- The company did not disclose specific production rate targets or obligated funding levels from the Air Force for 2027 and beyond.
Source: defence-industry.eu · Oct 23, 2026 · Drafted with Claude, reviewed by Industrial Base Alpha.
